February industry news: Alzheimer’s vaccine generates potent anti-pTau antibody response

Written by Neuro Central

In this month’s industry news round-up: positive interim results have been reported for an anti-pTau vaccine candidate in Alzheimer’s disease, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency has provided positive opinions for two drugs in patients with spinal muscular atrophy and relapsing multiple sclerosis, the US FDA approves an intramuscular route of administration for PLEGRIDY for patients with relapsing multiple sclerosis, and the European Commission has approved the expanded use of SPRAVATO® for the rapid reduction of depressive symptoms that constitute a psychiatric emergency. Take a look at February’s headlines below: Alzheimer’s vaccine...

To view this content, please register now for access

It's completely free